Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Pontificia Universidad Javeriana manages 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 4 distinct examiners across 3 distinct art units. QIAN, SHIZHI is the busiest examiner with 1 pending action, which is the same volume as the other examiners. For a practitioner, the fact that 4 pending office actions are spread across 4 different examiners means that no 1 examiner has a dominant influence over the portfolio.
The use of 3 distinct art units indicates that the university's pharmaceutical research is being reviewed in multiple specialized sections of the USPTO. This distribution requires the practitioner to manage 4 separate examiner relationships while coordinating across 3 distinct art unit standards. With 4 pending office actions, the administrative task involves tracking feedback from 4 different individuals. This variety provides a broad range of perspectives on the university's patentable subject matter but necessitates a highly organized approach to maintain consistency. The lack of concentration with any 1 examiner reduces the impact of a 1 negative or positive bias on the overall prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| QIAN, SHIZHI | 1 | 62.0% | +46.2% |
| CHUNDURU, SURYAPRABHA | 1 | 53.3% | +17.2% |
| XU, QING | 1 | 50.9% | +55.2% |
| GALSTER, SAMUEL LEONARD | 1 | 52.1% | +42.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557920 | METHOD FOR PRODUCING A BIOMODIFIED SENSOR FOR DETECTING AND MEASURING PATHOGENS | QIAN, SHIZHI | — |
| 18705551 | KIT FOR EVALUATING THROMBOMODULIN MRNA IN MATERNAL BLOOD FOR THE EARLY PREDICTION OF PRE-ECLAMPSIA | CHUNDURU, SURYAPRABHA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17640756 | COMPOSITIONS AND METHODS FOR COGNITIVE PROTECTION OF POLLINATORS AGAINST PESTICIDES | GALSTER, SAMUEL LEONARD | 23d |
| 18557920 | METHOD FOR PRODUCING A BIOMODIFIED SENSOR FOR DETECTING AND MEASURING PATHOGENS | QIAN, SHIZHI | — |
| 18705551 | KIT FOR EVALUATING THROMBOMODULIN MRNA IN MATERNAL BLOOD FOR THE EARLY PREDICTION OF PRE-ECLAMPSIA | CHUNDURU, SURYAPRABHA | — |
| 18006544 | METHOD TO SELECTIVELY PRODUCE METABOLITES FROM MICROALGAE OF THE GENUS GALDIERIA | XU, QING | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| 1656 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18557920 | METHOD FOR PRODUCING A BIOMODIFIED SENSOR FOR DETECTING AND MEASURING PATHOGENS | QIAN, SHIZHI | — | §103§112 | Non-Final OA | — | Pending | Aug 23, 2024 |
| 18705551 | KIT FOR EVALUATING THROMBOMODULIN MRNA IN MATERNAL BLOOD FOR THE EARLY PREDICTION OF PRE-ECLAMPSIA | CHUNDURU, SURYAPRABHA | 1681 | §101§102§103 | Non-Final OA | — | Pending | Apr 27, 2024 |
| 18006544 | METHOD TO SELECTIVELY PRODUCE METABOLITES FROM MICROALGAE OF THE GENUS GALDIERIA | XU, QING | 1656 | §103 | Final Rejection | — | Pending | Jan 23, 2023 |
| 17640756 | COMPOSITIONS AND METHODS FOR COGNITIVE PROTECTION OF POLLINATORS AGAINST PESTICIDES | GALSTER, SAMUEL LEONARD | 1693 | §103 | Final Rejection | 23d | Pending | Mar 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPontificia Universidad Javeriana has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Shizhi Qian has the most, with 1 of Pontificia Universidad Javeriana's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
